Emerging Advances in PET Imaging Software: An Interview with Subtle Medical’s Josh Gurewitz and Ajit Shankaranarayanan, PhD
In a recent interview, Josh Gurewitz and Ajit Shankaranarayanan, PhD, discussed the utility of AI-powered software, including the recently FDA-cleared SubtleHD(PET), for bolstering efficiency and quality with PET imaging.
In light of increasing demand for PET imaging, the recently FDA-cleared SubtleHD(PET) software may provide scan times up to 75 percent faster than conventional PET systems, according to Ajit Shankaranarayanan, PhD.
In a recent interview with Diagnostic Imaging, Dr. Shankaranarayanan said SubtleHD(PET) combines that efficiency with next-generation AI model architecture to facilitate improved image quality and benefits including improved SUVmax quantitative accuracy.
“What this actually gave us was a significantly improvement image enhancement performance, and also compatibility across all FDA-approved radiotracers,” pointed out Dr. Shankaranarayanan, the chief product officer for Subtle Medical, the developer of SubtleHD(PET).
The enhanced imaging quality with SubtleHD(PET) and its predecessor SubtlePET may offer significant value in oncology, according to Josh Gurewitz, MBA, the chief commercial officer for Subtle Medical.
“Such a large majority of PET imaging today is done in the oncology space, and the ability to have very high quality, potentially higher resolution images can make all the difference in the world. It makes reading the study potentially easier, but it also potentially can improve the ability to see small abnormalities in the region and potentially call them out,” added Gurewitz.
Looking further ahead, there is a broader strategic ambition. "The long-term strategic vision is to become a multimodality AI imaging hub," noted Dr Shankaranarayanan, who envisions a vendor-neutral enterprise platform that facilitates AI-driven acceleration with protocols, image enhancement, and workflow organization across existing scanner fleets.
Gurewitz underscored the importance of that vendor-agnostic approach.
"The ability to implement our unique AI tools on any scanner of all, literally almost any vintage with any software revision is critical, so that any patient on any scanner in any facility can potentially benefit from these unique tools,” maintained Gurewitz.
Related Content
